OakChart

Senti Biosciences Holdings Inc

SNTIHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.1572+0.0166 (11.81%)
2026-11-12 03:35 CET
Market cap
4.90 USD m
Revenue, TTM
0.06 USD m
Net income, TTM
-49.56 USD m
Free cash flow, TTM
-38.05 USD m
EPS diluted, TTM
-1.77
P/E
-
Compare

Price

SNTI against its 20, 50 and 200-day averages
2050200earnings
0.501.0043.7M87.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SNTIclose 0.1620-day 0.1950-day 0.27200-day 0.690.16

94.5% under the 52-week high of 2.88 on 9 Dec 2025. 52-week low 0.14 on 10 Nov 2026. Last 15 sessions, 72.5% high to low

Volume 0.06× normal · the line is the 50-bar volume average

Profile

SNTI
52-week range, 1% of the way up
0.142.88

Operates as a holding company whose subsidiary develops cell and gene therapies for cancer diseases

Employees39
IPOMay 26, 2021
Beta2.33
ATR, 14d0.03
Rel volume0.06
Short float3.58%
Insider own0.00%
Inst own6.69%

Snapshot

6 groups

Valuation

Index-
Market Cap4.90M
Enterprise Value18.67M
Income-49.56M
Sales0.06M
Book/sh-0.11
Cash/sh0.21
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees39
IPOMay 26, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S81.62
P/B-
P/C0.76
P/FCF-
EV/EBITDA-
EV/Sales311.12
Quick Ratio0.83
Current Ratio0.83
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.77
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y50.33% 65.37%
Sales past 3/5Y-82.75% -70.12%
EPS Y/Y TTM80.28%
Sales Y/Y TTM-
EPS Q/Q27.53%
Sales Q/Q-
EarningsAug 18
EPS/Sales Surpr.61.11% -

Ownership

Insider Own0.00%
Insider Trans-
Inst Own6.69%
Inst Trans0.65%
ROA-97.52%
ROE-466.46%
ROIC-530.66%
Gross Margin-5630.91%
Oper. Margin-102761.82%
Profit Margin-90116.36%
SMA20-17.69%
SMA50-40.74%
SMA200-77.15%
Trades-

Technical

Shs Outstand31.15M
Shs Float31.15M
Short Float3.58%
Short Ratio0.32
Short Interest1.12M
52W High2.88 -94.54%
52W Low0.14 14.16%
Volatility12.16% 14.73%
ATR (14)0.03
RSI (14)34.88
Beta2.33
Rel Volume0.06
Avg Volume3.51M
Volume225,293

Performance

Perf Week-10.99%
Perf Month-38.35%
Perf Quarter-59.06%
Perf Half Y-83.68%
Perf YTD-84.88%
Perf Year-91.41%
Perf 3Y-96.97%
Perf 5Y-99.84%
Perf 10Y-
Recom1.00
Target Price15.00
Prev Close0.14
Price0.16
Change %11.81%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Oct 14, 2025InitiatedHH.C. WainwrightBuy$12+7,533.6%
Jun 06, 2025InitiatedLLaidlawBuy$5+3,080.7%
Oct 07, 2022InitiatedMMorgan StanleyEqual-Weight$7.50+4,671.0%

Peers

Mkt cap
TickerCompanyMkt cap
FATEFate Therapeutics Inc195.12M
NKTXNkarta Inc106.12M
GTBPGT Biopharma Inc8.14M
ARTVArtiva Biotherapeutics Inc201.19M
IPSCCentury Therapeutics Inc315.07M
CRBUCaribou Biosciences Inc42.21M
INKTMiNK Therapeutics Inc52.17M
ACETAdicet Bio Inc27.99M
GDTCCytoMed Therapeutics Ltd9.94M
ATRAAtara Biotherapeutics Inc82.61M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial Technology Platform (GlobeNewswire) -39.71%
  • The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change (Business Wire)
  • Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase (GlobeNewswire) +8.00%
  • Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program (GlobeNewswire)
  • Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 (GlobeNewswire)
  • Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies (GlobeNewswire)
  • Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) -10.36%
  • Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference (GlobeNewswire)
  • Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
  • Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +7.08%
  • Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development (GlobeNewswire)
  • Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) (GlobeNewswire)
  • Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 (GlobeNewswire)
  • Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-18-0.200-0.265-0.6900.000.002
2026Q12026-05-14-0.140-0.360-0.6900.010.003
2025Q42026-03-27-0.530-0.413-0.5280.021.004
2025Q32025-11-13-0.690-0.567-0.6910.000.253
2025Q22025-08-07-0.560-0.900-0.5650.000.502
2025Q12025-05-06-1.410-0.560-1.4090.001.301
2024Q42025-03-20-0.670-3.130-0.6722.802.801
2024Q32024-11-14-6.310--6.3070.34--
2024Q22024-08-13-2.450--2.4500.34--
2024Q12024-05-09-2.600--2.6500.34--
2023Q42024-03-21-4.200-4.200-4.191-0.621
2023Q32023-11-13-3.400-4.420-3.3560.340.673
2023Q22023-08-11-4.200-4.767-4.2230.940.503
2023Q12023-05-09-4.200-4.333-4.2481.290.473
2022Q42023-03-22-4.200-4.386-4.1550.061.514
2022Q32022-11-10-3.800-4.567-3.8321.770.933

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-22.300-17.825-22.2944.295.37
2023FY-16.000--20.9412.56-
2024FY-12.030-14.540-12.0352.802.80
2025FY-2.730-2.645-12.0300.021.00
2026FY--0.780--0.02
2027FY--0.960---
2028FY--1.610---
2029FY--1.420--56.50
2030FY-0.560--213.51

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-181000.000.000.00
2026Q3S2026-07-301000.000.000.00
2026Q3S2026-05-142000.000.000.00
2026Q3S2026-03-272000.000.000.00
2026Q3S2025-11-141000.000.000.00
2026Q3R2025-11-20200-0.41-0.50-0.31
2026Q3R2025-11-14100-0.31-0.31-0.31
2026Q3E2026-08-22100-0.21-0.21-0.21
2026Q3E2026-08-18200-0.30-0.38-0.21
2026Q3E2026-07-30200-0.30-0.38-0.21
2026Q3E2026-07-29300-0.35-0.45-0.21
2026Q3E2026-07-28310-0.35-0.45-0.21
2026Q3E2026-05-15321-0.35-0.45-0.21
2026Q3E2026-05-14311-0.37-0.45-0.28

Estimate history

EPS, annual-189.951-22.294-20.941-12.035-2.733-1.7651
Period20212022202320242025TTM
EPS, quarterly-2.45-6.307-0.672-1.409-0.565-0.691-0.528-0.136-0.409
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.7614.2862.56100.0220.06
Period20212022202320242025TTM
Sales, quarterly0000000.0220.0160.017
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.2494.4064.574.82930.87931.145
Period20212022202320242025MRQ
Shares, quarterly4.5724.5874.82926.00426.1626.29130.87931.14531.145
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.060.020.002.564.292.76
Cost of Goods Sold Incl. D&A3.153.645.855.243.893.01
Gross Profit-3.10-3.62-5.85-2.680.40-0.25
Selling, General and Administrative Excl. Other53.4260.1154.8864.0862.4840.20
Research and Development30.4536.6833.3831.0827.3718.95
Other Operating Expense0.000.000.000.000.000.00
Operating Income-56.52-63.73-60.73-66.77-62.08-40.45
Interest Expense----0.000.00
Unusual Expense-2.105.05-0.3921.80-10.7514.76
Net Income Before Taxes-49.56-61.44-52.79-83.41-49.66-55.32
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-49.56-61.44-52.79-83.41-49.66-55.32
Net Income From Continuing Operations-49.56-61.44-52.79-83.41-49.66-55.32
Net Income-49.56-61.44-55.31-92.92-58.21-55.32
EPS (Recurring)-1.64-2.58-12.09-17.50-25.18-154.46
EPS (Basic, Before Extraordinaries)-1.77-2.73-12.04-20.94-22.29-189.95
EPS (Diluted)-1.77-2.73-12.04-20.94-22.29-189.95
EBITDA-53.37-60.09-54.88-61.52-58.20-37.44
Non-Operating Income (Expense)4.857.347.555.151.67-0.11
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense5.345.711.759.6716.392.29
Price To Sales Ratio622.901,062.85-11.448.5910.40
Gross Margin-5,630.91-16,431.82--104.769.26-9.02
Operating Margin-102,761.82-289,668.18--2,606.99-1,448.53-1,464.90
Net Margin-90,116.36-279,263.64--3,628.23-1,358.14-2,003.59
Shares Outstanding31.1430.884.834.574.412.25
Market Capitalization4.904.90----

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.020.020.020.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.670.690.890.900.920.931.461.46
Gross Profit-0.65-0.67-0.87-0.90-0.92-0.93-1.46-1.46
Selling, General and Administrative Excl. Other13.8410.8312.7116.0415.8815.4714.7113.44
Research and Development7.575.067.5310.299.809.067.548.42
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.49-11.50-13.58-16.95-16.80-16.40-16.17-14.90
Interest Expense---0.000.000.00--
Unusual Expense-0.27-6.885.050.000.000.00-13.4215.76
Net Income Before Taxes-12.75-4.22-14.47-18.13-14.73-14.11-0.61-28.87
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.75-4.22-14.47-18.13-14.73-14.11-0.61-28.87
Net Income From Continuing Operations-12.75-4.22-14.47-18.13-14.73-14.11-0.61-28.87
Net Income-12.75-4.22-14.47-18.13-14.73-14.11-3.13-28.87
EPS (Recurring)-0.42-0.29-0.40-0.69-0.56-1.41-2.69-3.90
EPS (Basic, Before Extraordinaries)-0.41-0.14-0.53-0.69-0.56-1.41-0.67-6.31
EPS (Diluted)-0.41-0.14-0.53-0.69-0.56-1.41-0.67-6.31
EBITDA-13.82-10.81-12.69-16.04-15.88-15.47-14.71-13.44
Non-Operating Income (Expense)1.470.404.17-1.182.062.292.131.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.051.311.431.551.531.200.600.67
Price To Sales Ratio622.90661.811,294.34-----
Gross Margin-3,823.53-4,200.00-3,959.09-----
Operating Margin-85,229.41-71,862.50-61,745.45-----
Net Margin-75,000.00-26,381.25-65,759.09-----
Shares Outstanding31.1431.1430.8826.2926.1626.004.834.59
Market Capitalization4.9034.57------

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments16.4248.2835.9398.5656.03
Short Term Receivables1.591.8017.700.630.48
Inventories0.000.000.000.000.00
Other Current Assets5.268.8817.573.392.23
Total Current Assets23.2758.9671.20102.5858.75
Net Property, Plant & Equipment24.4035.2441.6169.7833.08
Total Investments and Advances3.533.543.523.373.26
Long-Term Note Receivable-0.001.120.00-
Intangible Assets----0.00
Other Assets0.020.102.035.071.62
Total Assets51.2297.84119.48180.7996.70
Short Term Debt Incl. Current Port. of LT Debt5.334.754.131.991.74
Accounts Payable2.941.451.251.375.19
Other Current Liabilities5.706.947.2914.707.61
Total Current Liabilities13.9713.1512.6718.0514.54
Long Term Debt23.5628.8933.5435.1020.99
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities8.105.056.360.370.80
Total Liabilities45.6347.0952.5753.5336.33
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.0025.110.000.00171.83
Common Equity5.5925.6566.91127.26-111.46
Total Shareholders Equity5.5950.7666.91127.2660.38
Accumulated Minority Interest0.000.000.000.000.00
Total Equity5.5950.7666.91127.2660.38
Total Liabilities & Stockholders Equity51.2297.84119.48180.7996.70
Book Value Per Share0.185.3114.6428.88-49.56
Tangible Book Value Per Share0.185.3114.6428.88-49.56
Full-Time Employees3934481224
Price to Book Ratio-1.44----
Return on Assets-82.43-48.58-55.55-35.80-
Return on Equity-218.08-89.73-85.91-52.94-
Return on Invested Capital-210.77-66.28-92.50-35.85-67.99
Quick Ratio1.674.495.625.684.04
Current Ratio1.674.495.625.684.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-49.56-61.44-52.79-71.06-58.21-55.32
Depreciation3.153.645.855.243.893.01
Other Funds (Non Cash)3.7110.801.508.755.5217.06
Funds from Operations-42.70-47.00-45.44-57.06-48.80-35.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.653.564.044.6713.900.61
Cash from Operating Activities-38.05-43.44-41.40-52.40-34.90-34.63
Capital Expenditures0.00-0.20-0.03-12.04-41.37-5.54
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.110.010.060.100.000.00
Purchase or Sale of Investments0.000.000.0042.01-40.590.00
Purchase of Investments0.000.000.00-17.99-40.590.00
Sale Or Maturity of Investments0.000.000.0060.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.11-0.180.0330.08-81.96-5.54
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock10.618.7148.830.891.401.50
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock10.618.7148.830.891.401.50
Proceedsfrom Stock Options-0.57-2.4747.020.510.730.00
Issuance or Reduction of Debt, Net9.700.000.00-0.110.000.00
Change in Long Term Debt0.000.000.00-0.110.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.110.000.00
Net Financing Active Other Cash Flow0.413.054.900.00117.15-0.02
Other Financing Activities Uses-0.120.000.000.000.00-0.02
Cash from Financing Activities20.7211.7653.730.78118.5568.44
Net Change in Cash-17.22-31.8712.37-21.541.7028.26
Free Cash Flow-38.05-43.64-41.42-64.43-76.27-40.18
Preferred Dividends (Cash Flow)-0.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.468.9416.4212.2421.5833.80
Short Term Receivables0.560.771.591.743.692.22
Inventories0.000.000.000.000.000.00
Other Current Assets5.995.095.264.177.259.19
Total Current Assets13.0114.7923.2718.1632.5245.21
Net Property, Plant & Equipment18.6719.9224.4030.9532.4433.94
Total Investments and Advances1.433.533.533.543.533.55
Intangible Assets0.00-----
Other Assets0.000.010.020.030.050.08
Total Assets33.1038.2451.2252.6968.5482.78
Short Term Debt Incl. Current Port. of LT Debt7.495.895.335.154.984.81
Accounts Payable2.251.052.941.771.021.56
Other Current Liabilities6.037.335.705.103.994.36
Total Current Liabilities15.7714.2713.9712.039.9910.73
Long Term Debt12.7413.2523.5624.9726.3327.63
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities8.008.168.100.150.150.15
Total Liabilities36.5135.6845.6337.1436.4738.51
Non-Equity Reserves0.000.000.007.427.426.41
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-3.402.565.598.1224.6537.86
Total Shareholders Equity-3.402.565.598.1224.6537.86
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-3.402.565.598.1224.6537.86
Total Liabilities & Stockholders Equity33.1038.2451.2252.6968.5482.78
Book Value Per Share-0.110.080.180.310.941.46
Tangible Book Value Per Share-0.110.080.180.310.941.46
Full-Time Employees--39---
Price to Book Ratio-1.4413.48----
Return on Assets-97.52-85.19-82.43-86.19-75.03-59.25
Return on Equity-466.46-255.03-218.08-394.62-169.54-116.63
Return on Invested Capital-136.51-26.69-49.63-54.78-28.90-21.55
Quick Ratio0.831.041.671.513.264.22
Current Ratio0.831.041.671.513.264.22

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-12.75-4.22-14.47-18.13-14.73-14.11
Depreciation0.670.690.890.900.910.93
Other Funds (Non Cash)1.08-5.396.481.551.561.20
Funds from Operations-11.01-8.93-7.10-15.67-12.25-11.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.241.450.226.22-0.82-2.07
Cash from Operating Activities-14.25-7.48-6.88-9.45-13.07-14.05
Capital Expenditures0.000.000.000.00-0.200.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.110.000.000.010.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.110.000.00-0.180.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.030.0010.510.120.00-1.92
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.030.0010.510.120.00-1.92
Proceedsfrom Stock Options-0.030.00-0.670.120.00-1.92
Issuance or Reduction of Debt, Net9.700.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.120.530.001.011.51
Other Financing Activities Uses0.00-0.120.000.000.000.00
Cash from Financing Activities9.68-0.1211.040.121.01-0.41
Net Change in Cash-4.57-7.494.17-9.32-12.25-14.46
Free Cash Flow-14.25-7.48-6.88-9.45-13.27-14.05

Revenue breakdown

Biological Products, (No Diagnostic Substances)2025: 22.00K
United States2025: 22.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.58%1.1M31.2M3.48M
2026-10-151.37%0.4M31.2M823.51K
2026-09-306.14%0.5M7.9M555.87K
2026-09-156.35%0.5M8.0M253.51K
2026-08-311.68%0.5M31.1M259.07K
2026-08-141.67%0.5M31.1M250.92K
2026-07-311.86%0.6M31.1M256.42K
2026-07-151.94%0.6M31.1M242.98K
2026-06-306.75%0.5M8.0M197.90K
2026-06-152.03%0.6M31.1M183.99K
2026-05-297.08%0.6M8.0M174.40K
2026-05-158.51%0.6M7.6M166.70K
2026-04-302.14%0.7M31.1M165.93K
2026-04-155.53%0.7M11.8M164.96K
2026-03-319.57%0.7M7.7M192.73K
2026-03-1311.58%0.8M6.5M279.69K
2026-02-2712.54%0.8M6.5M1.63M
2026-02-1312.91%0.8M6.5M1.62M
2026-01-3012.00%0.8M6.3M1.60M
2026-01-1511.68%0.8M6.8M1.55M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-09SEC
2026-10-278-KCurrent report2026-10-26SEC
2026-10-268-KCurrent report2026-10-21SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-13DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-138-KCurrent report2026-10-08SEC
2026-09-24EFFECTEffectiveness filing by commission orderSEC
2026-09-248-KCurrent report2026-09-23SEC
2026-09-24424B3SEC
2026-09-24DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-24PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-22S-3/ASEC
2026-09-11SCHEDULE 13D/ASEC
2026-09-10S-3/ASEC
2026-09-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-048-KCurrent report2026-09-03SEC
2026-09-04PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-02DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-028-KCurrent report2026-08-27SEC
2026-08-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-208-KCurrent report2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-21ARSAnnual report to security holders. 2025-12-31SEC
2026-07-21PREM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-18SEC
2026-07-16S-3/ASEC
2026-07-16SCHEDULE 13D/ASEC
2026-07-15DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-158-KCurrent report2026-07-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
NEA Management Company, LLC12.12%
Nantahala Capital Management, LLC2.85%
VANGUARD CAPITAL MANAGEMENT LLC1.73%
GEODE CAPITAL MANAGEMENT, LLC0.57%
CITADEL ADVISORS LLC0.34%
VANGUARD FIDUCIARY TRUST CO0.29%
JANE STREET GROUP, LLC0.17%
Menlo Ventures Management, L.P.0.11%
NORTHERN TRUST CORP0.10%
XTX Topco Ltd0.08%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.18%
VANGUARD EXTENDED MARKET INDEX FUND0.54%
Fidelity Extended Market Index Fund0.31%
Fidelity Nasdaq Composite Index Fund0.08%
Fidelity Total Market Index Fund0.06%
Fidelity Series Total Market Index Fund0.06%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. SNTI. Cached 15 minutes.

Some panels did not load: insider.